Get notified when ADTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Ceo (new) — The Chief Executive Officer resigned effective May 31, 2026, followed immediately by the COO's resignation.
Aditxt CEO Amro Albanna resigns; Jeffrey Busch named Interim CEO amid C-suite shakeup
Filed June 1, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
high
CEO Amro Albanna resigned effective May 31, 2026, and also stepped down from the Board of Directors. The company states his departure was not due to any disagreement on operations or policies.
Item 5.02 verify on EDGAR → -
high
Jeffrey M. Busch, 68, appointed Interim CEO effective May 31 with $500,000 annual salary. Busch previously founded Global Medical REIT (NYSE: GMRE) and currently leads Ignite Proteomics, an Aditxt subsidiary.
Item 5.02 verify on EDGAR → -
high
COO Rowena Albanna resigned effective June 5, 2026, marking the second C-suite departure within days of the CEO's exit.
Item 5.02 verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FNGR 10-Q) is open in full — no account needed.
Partner
Trade ADTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify